A low TSH profile predicts olanzapine-induced weight gain and relief by adjunctive topiramate in healthy male volunteers

Psychoneuroendocrinology
Simon S EversGertjan van Dijk

Abstract

Second generation antipsychotics, like olanzapine (OLZ), have become the first line drug treatment for patients with schizophrenia. However, OLZ treatment is often associated with body weight (BW) gain and metabolic derangements. Therefore, the search for prospective markers for OLZ's negative side effects as well as adjunctive treatments to inhibit these has been of major interest. The aim of this study was to investigate in healthy male volunteers (age: 36 ± 11 years; BW: 84 ± 12 kg; BMI=25.5 ± 2.5) whether adjunctive topiramate (TPM) administration opposes OLZ-induced weight gain over the course of 14 days treatment. In addition, we investigated behavioral, endocrine and metabolic characteristics as underlying and potentially predictive factors for weight regulation and/or metabolic derangements associated with OLZ and TPM treatment. While adjunctive TPM indeed reduced OLZ-induced weight gain (P<0.05, Mann-Whitney U), behavioral/metabolic/endocrine characteristics of OLZ treatment were not affected by TPM. Using multiple regression analysis, BW gain was the key factor explaining metabolic disturbances (e.g., plasma insulin- LDL interaction: P<0.01, R(2)=.320), and cumulative food intake during treatment was the best denomina...Continue Reading

References

Jan 1, 1984·European Archives of Psychiatry and Neurological Sciences·M L RaoG Huber
Jun 1, 1995·Archives of General Psychiatry·G D PearlsonH N Wagner
Jan 1, 1996·Comprehensive Psychiatry·S MukherjeeP L Scapicchio
Sep 21, 2000·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·E RotiM Salvi
Feb 4, 2003·The American Journal of Psychiatry·Jean-Pierre LindenmayerJeffrey A Lieberman
Mar 16, 2004·Psychosomatics·David M Blass, Michelle Chuen
Jun 5, 2004·Psychoneuroendocrinology·J K LarsenK Siersbaek-Nielsen
Jul 3, 2004·Journal of Clinical Psychopharmacology·Eduard VietaEsteve Brugue
Dec 31, 2004·The American Journal of Psychiatry·Karen A GrahamJoyce B Harp
Apr 6, 2005·Annals of Internal Medicine·Zhaoping LiSally C Morton
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Sep 28, 2005·Psychoneuroendocrinology·Klaus MannChristoph Hiemke
May 20, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Murray A RaskindDennis D Rasmussen
Apr 3, 2007·European Journal of Clinical Pharmacology·Rob J van MarumErna Beers
Aug 22, 2007·Nature Clinical Practice. Endocrinology & Metabolism·Gabriela BrentaIrwin Klein
Feb 26, 2008·Journal of Child and Adolescent Psychopharmacology·Jeffrey R StrawnMelissa P DelBello
Mar 7, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nicholas M WallingfordMichael A Cowley
Jul 1, 1992·Trends in Endocrinology and Metabolism : TEM·G BrabantC Schofl
Mar 17, 2009·European Psychiatry : the Journal of the Association of European Psychiatrists·F C J Starrenburg, J P A M Bogers
Nov 13, 2009·The Journal of Clinical Endocrinology and Metabolism·Solrun VidarsdottirHanno Pijl
Jun 24, 2010·Pharmacology, Biochemistry, and Behavior·S S EversA J W Scheurink
Aug 19, 2010·Current Opinion in Endocrinology, Diabetes, and Obesity·Pornpoj Pramyothin, Lalita Khaodhiar
Apr 26, 2014·PloS One·Maarten BakMarjan Drukker
Dec 15, 2015·Rapid Communications in Mass Spectrometry : RCM·Stefano GuidottiGertjan van Dijk

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Related Papers

The American Journal of Psychiatry
U EderW Wolfgang Fleischhacker
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
F M M A van der HeijdenW M A Verhoeven
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
Joachim CordesHans Hauner
© 2022 Meta ULC. All rights reserved